AI in Healthcare

CAR-T therapy trials paused amid life-threatening side effects raises serious questions about safety oversight in AI-driven drug development. According to STAT News, Bristol Meyers Squibb halted its autoimmune disease trial after three deaths were reported in similar Novartis studies, highlighting a gap in transparency that could impact the entire biotech ecosystem. What does this mean for future regulatory frameworks around AI-assisted therapy design? Source: https://www.statnews.com/pharmalot/2026/09/04/pharmalittle-bristol-car-t-trial-pause-pfizer-offloads-shelved-candidate/?utm_campaign=rss View and join any or all of our communities — AI, quantum, and real estate: https://alex-companies.com/reports/linkedin-groups If there's an AI, quantum, or real estate community you'd like to see us convene, tell us — this portfolio grows by request. MIT, Nvidia, Google & IBM-Trained. Cross Domain-Expert: Quantum, AI, Ethics, Sovereignty, Intelligence, Philanthropy. Solepoint Planning. VUI AI Cloud Architect. AI Certifications Development. Quant/AI Instructor. Castor Venture Club Member. Associate Broker. George Arnold Alexander III Director, ALEX Companies; Associate Broker, Alexander Tiffany Southwest, LLC. +1 713.918.9951 · [email protected]